CLINUVEL delivers ninth consecutive revenues growth & profit

• Revenues grew by 10% to $105.3 million
• Net profit before tax increased by 2% to $51.6 million
• Cash reserves increased by 22% to $224.1 million
• Eighth consecutive annual dividend of $0.05 per share

CLINUVEL Pharmaceuticals Ltd has announced its ninth consecutive profit of $51.6 million before tax and $36.2 million after tax for the fiscal year ending 30 June 2025 (FY2025). Revenues grew by 10% to $105.3 million in FY2025 from sales of SCENESSE® (afamelanotide 16mg) to treat erythropoietic protoporphyria (EPP) patients, primarily in Europe and the USA. Expenses grew by 20% to $53.7 million in FY2025, reflecting the Company's direct and indirect costs associated with its clinical program for vitiligo. CLINUVEL's strengthened balance sheet holds net assets of $240.8 million as of 30 June 2025. Positive annual net cash inflow from commercial operations of $41.1 million have built cash reserves, enabling the Company to self-finance its diversification plans and provide a buffer to manage risks in a volatile macroeconomic environment. Cash reserves increased by 22% to $224.1 million during FY2025. The CLINUVEL Board has declared an annual franked dividend of $0.05 per ordinary share following the FY2025 financial results - this is the eighth consecutive annual dividend and fourth fully franked.